GlaxoSmithKline ( (GB:GSK) ) has shared an update.
GSK has announced the purchase of 556,200 of its own ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction, which took place on March 19, 2025, is part of a non-discretionary agreement and highlights GSK’s strategic efforts to manage its capital structure and enhance shareholder value. The shares will be held as treasury shares, and the total number of voting rights remains unchanged at 4,133,820,322, providing stakeholders with a clear understanding of their shareholding status.
More about GlaxoSmithKline
GlaxoSmithKline (GSK) is a leading global healthcare company engaged in the pharmaceutical industry, focusing on the development and distribution of medicines, vaccines, and consumer healthcare products. The company is committed to improving the quality of human life by enabling people to do more, feel better, and live longer.
YTD Price Performance: 13.03%
Average Trading Volume: 8,323,003
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: £62.34B
For detailed information about GSK stock, go to TipRanks’ Stock Analysis page.